{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:51:49Z","timestamp":1792165909320,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00204-024-03859-3","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T11:09:18Z","timestamp":1726052958000},"page":"4159-4172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Escaping the cohort of concern: in vitro experimental evidence supports non-mutagenicity of N-nitroso-hydrochlorothiazide"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6697-5308","authenticated-orcid":false,"given":"R. D.","family":"Gandhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Hoevelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Mee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-1086","authenticated-orcid":false,"given":"J.","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9280-8469","authenticated-orcid":false,"given":"A.","family":"Blanazs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2497-5211","authenticated-orcid":false,"given":"S.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Elloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4107-6046","authenticated-orcid":false,"given":"L.","family":"Rigger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Teasdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6796-7449","authenticated-orcid":false,"given":"C. V.","family":"Beaumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"6","key":"3859_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/mutage\/10.6.517","volume":"10","author":"RD Callander","year":"1995","unstructured":"Callander RD, Mackay JM, Clay P, Elcombe CR, Elliott BM (1995) Evaluation of phenobarbital\/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays. Mutagenesis 10(6):517\u2013522. https:\/\/doi.org\/10.1093\/mutage\/10.6.517","journal-title":"Mutagenesis"},{"key":"3859_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.comtox.2021.100186","volume":"20","author":"KP Cross","year":"2021","unstructured":"Cross KP, Ponting DJ (2021) Developing structure-activity relationships for N-nitrosamine activity. Comput Toxicol 20:100186. https:\/\/doi.org\/10.1016\/j.comtox.2021.100186","journal-title":"Comput Toxicol"},{"key":"3859_CR3","first-page":"405","volume-title":"Analytical profiles of drug substances","author":"HP Deppeler","year":"1981","unstructured":"Deppeler HP (1981) Hydrochlorothiazide. In: Florey K, Bishara R, Brewer GA et al (eds) Analytical profiles of drug substances, vol 10. Academic Press, Cambridge, pp 405\u2013441"},{"key":"3859_CR4","unstructured":"efpia (2022) Position Paper: Investigation into potential N-nitrosation and the specific nature of nitroso HCTZ. https:\/\/www.efpia.eu\/media\/677166\/white-paper-hydrochlorothiazide-investigation-into-potential-n-nitrosation.pdf."},{"issue":"3","key":"3859_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1093\/mutage\/7.3.175","volume":"7","author":"BM Elliott","year":"1992","unstructured":"Elliott BM, Combes RD, Elcombe CR et al (1992) Alternatives to Aroclor 1254-induced S9 in in vitro genotoxicity assays. Mutagenesis 7(3):175\u2013177. https:\/\/doi.org\/10.1093\/mutage\/7.3.175","journal-title":"Mutagenesis"},{"key":"3859_CR6","unstructured":"EMA (2023) Appendix 2 to Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 26\/2004 referral on nitrosamine impurities in human medicinal products - Carcinogenic Potency Categorisation Approach for N-nitrosamines. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-carcinogenic-potency-categorisation-approach-n-nitrosamines_en.pdf. Accessed 6 OCT 2023"},{"key":"3859_CR7","unstructured":"EMA (2024a) Appendix 1 to Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 26\/2004 referral on nitrosamine impurities in human medicinal products - Acceptable intakes established for N-nitrosamines. https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-1-acceptable-intakes-established-n-nitrosamines_en.xlsx. Accessed 30 May 2024"},{"key":"3859_CR8","unstructured":"EMA (2024b) Questions and answers on \u201cInformation on nitrosamines for marketing authorisation holders\" (EMA\/409815\/2020). https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf."},{"key":"3859_CR9","unstructured":"EMA\/CHMP (2020) Procedure under Article 5(3) of Regulation EC (No) 726\/2004; Assessment report: Nitrosamine impurities in human medicinal products (EMA\/369136\/2020). https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf. Accessed 6 Oct 2023"},{"issue":"1","key":"3859_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0009-2797(92)90024-F","volume":"81","author":"GP Ford","year":"1992","unstructured":"Ford GP, Griffin GR (1992) Relative stabilities of nitrenium ions derived from heterocyclic amine food carcinogens: Relationship to mutagenicity. Chem Biol Interact 81(1):19\u201333. https:\/\/doi.org\/10.1016\/0009-2797(92)90024-F","journal-title":"Chem Biol Interact"},{"issue":"10","key":"3859_CR11","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1021\/acs.oprd.3c00119","volume":"27","author":"R Grahek","year":"2023","unstructured":"Grahek R, Drev M, Zupan\u010di\u010d B et al (2023) Stability and degradation pathways of N-nitroso-hydrochlorothiazide and the corresponding aryl diazonium ion. Org Process Res Dev 27(10):1792\u20131811. https:\/\/doi.org\/10.1021\/acs.oprd.3c00119","journal-title":"Org Process Res Dev"},{"key":"3859_CR12","unstructured":"Health Canada (2024) Nitrosamine impurities in medications: Established acceptable intake limits. https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/nitrosamine-impurities\/established-acceptable-intake-limits.html."},{"key":"3859_CR13","volume-title":"Hydrochlorothiazide StatPearls","author":"LL Herman","year":"2024","unstructured":"Herman LL, Weber P, Bashir K (2024) Hydrochlorothiazide StatPearls. StatPearls Publishing, St. Petersburg"},{"key":"3859_CR14","unstructured":"Copyright \u00a9 2024, StatPearls Publishing LLC., Treasure Island (FL)"},{"issue":"21","key":"3859_CR15","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1039\/C0OB00208A","volume":"8","author":"RJ Hopkinson","year":"2010","unstructured":"Hopkinson RJ, Barlow PS, Schofield CJ, Claridge TDW (2010) Studies on the reaction of glutathione and formaldehyde using NMR. Org Biomol Chem 8(21):4915\u20134920. https:\/\/doi.org\/10.1039\/C0OB00208A","journal-title":"Org Biomol Chem"},{"key":"3859_CR16","unstructured":"ICH (2023) Addendum to M7(R2): Application of the Principles of the ICH M7 Guideline to Calculation of Compund-Specific Acceptable Intakes"},{"key":"3859_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fenvs.2014.00036","author":"M Kawanishi","year":"2014","unstructured":"Kawanishi M, Matsuda T, Yagi T (2014) Genotoxicity of formaldehyde: molecular basis of DNA damage and mutation. Front Environ Sci. https:\/\/doi.org\/10.3389\/fenvs.2014.00036","journal-title":"Front Environ Sci"},{"key":"3859_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev.pharmtox.45.120403.100010","volume":"45","author":"D Kim","year":"2005","unstructured":"Kim D, Guengerich FP (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu Rev Pharmacol Toxicol 45:27\u201349. https:\/\/doi.org\/10.1146\/annurev.pharmtox.45.120403.100010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"3859_CR20","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.3390\/ijms23094559","volume":"23","author":"Y Li","year":"2022","unstructured":"Li Y, Hecht SS (2022) Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. Int J Mol Sci 23(9):4559","journal-title":"Int J Mol Sci"},{"key":"3859_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105410","volume":"141","author":"X Li","year":"2023","unstructured":"Li X, Le Y, Seo J-E et al (2023) Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays. Regul Toxicol Pharmacol 141:105410. https:\/\/doi.org\/10.1016\/j.yrtph.2023.105410","journal-title":"Regul Toxicol Pharmacol"},{"issue":"3","key":"3859_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0165-1161(83)90010-9","volume":"113","author":"DM Maron","year":"1983","unstructured":"Maron DM, Ames BN (1983) Revised methods for the Salmonella mutagenicity test. Mutat Res Environ Mutagen Relat Subj 113(3):173\u2013215. https:\/\/doi.org\/10.1016\/0165-1161(83)90010-9","journal-title":"Mutat Res Environ Mutagen Relat Subj"},{"issue":"1","key":"3859_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0027-5107(00)00076-2","volume":"455","author":"K Mortelmans","year":"2000","unstructured":"Mortelmans K, Riccio ES (2000) The bacterial tryptophan reverse mutation assay with Escherichia coli WP2. Mutat Res Fundam Mol Mech Mutagen 455(1):61\u201369. https:\/\/doi.org\/10.1016\/S0027-5107(00)00076-2","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"issue":"1","key":"3859_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0027-5107(00)00064-6","volume":"455","author":"K Mortelmans","year":"2000","unstructured":"Mortelmans K, Zeiger E (2000) The Ames Salmonella\/microsome mutagenicity assay. Mutat Res Fundam Mol Mech Mutagen 455(1):29\u201360. https:\/\/doi.org\/10.1016\/S0027-5107(00)00064-6","journal-title":"Mutat Res Fundam Mol Mech Mutagen"},{"key":"3859_CR24","unstructured":"OECD (2020) Test No. 471: Bacterial Reverse Mutation Test"},{"issue":"5","key":"3859_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/carcin\/12.5.759","volume":"12","author":"M Paolini","year":"1991","unstructured":"Paolini M, Sapigni E, Hrelia P, Scotti M, Morotti M, Cantelli-Forti G (1991) Wide spectrum detection of precarcinogens in short-term bioassays by simultaneous superinduction of multiple forms of cytochrome P450 isoenzymes. Carcinogenesis 12(5):759\u2013766. https:\/\/doi.org\/10.1093\/carcin\/12.5.759","journal-title":"Carcinogenesis"},{"issue":"327","key":"3859_CR26","first-page":"991","volume":"39","author":"JEF Reynolds","year":"1989","unstructured":"Reynolds JEF (1989) Martindale: the extra pharmacopoeia (29th edition). J R Coll Gen Pract 39(327):991\u2013993","journal-title":"J R Coll Gen Pract"},{"issue":"12","key":"3859_CR27","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1751-7176.2011.00566.x","volume":"13","author":"C Rosendorff","year":"2011","unstructured":"Rosendorff C (2011) Why are we still using hydrochlorothiazide? J Clin Hypertens (Greenwich) 13(12):867\u2013869. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00566.x","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"27","key":"3859_CR28","doi-asserted-by":"publisher","first-page":"6596","DOI":"10.1016\/j.tet.2005.04.050","volume":"61","author":"YA Simonov","year":"2005","unstructured":"Simonov YA, Fonari MS, Duca GG et al (2005) Nitrosation of hydrochlorothiazide and the modes of binding of the N-nitroso derivative with two macrocycles possessing an 18-membered crown ether cavity. Tetrahedron 61(27):6596\u20136601. https:\/\/doi.org\/10.1016\/j.tet.2005.04.050","journal-title":"Tetrahedron"},{"issue":"3","key":"3859_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0165-1218(85)90058-8","volume":"156","author":"K Takahashi","year":"1985","unstructured":"Takahashi K, Morita T, Kawazoe Y (1985) Mutagenic characteristics of formaldehyde on bacterial systems. Mutat Res 156(3):153\u2013161. https:\/\/doi.org\/10.1016\/0165-1218(85)90058-8","journal-title":"Mutat Res"},{"key":"3859_CR30","first-page":"45","volume-title":"Mutagenicity testing a practical approach","author":"S Venitt","year":"1984","unstructured":"Venitt S, Crofton-Sleigh C, Forster R (1984) Bacterial mutation assays using reverse mutation. In: Venitt S, Parry JM (eds) Mutagenicity testing a practical approach. IRL Press, Oxford, pp 45\u201398"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03859-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T13:04:08Z","timestamp":1729602248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03859-3","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain clinical studies or patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are employed by their respective affiliations. Gandhi RD, Adams A, Blanazs A, Doherty A, Elloway J, Teasdale A, Beaumont CV, Wright L are employees of AstraZeneca and have stock ownership and\/or stock options or interests in the company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}